Today we're sharing that Medsync has closed an angel funding round. This is a milestone worth acknowledging — not because the amount changes everything (angel rounds rarely do, and we've been clear-eyed about what this stage of company means), but because it represents an external validation of the problem we're working on and gives us the runway to build the next phase of the product more deliberately.
I founded Medsync in 2022 alongside my co-founder because we kept running into the same operational bottleneck in specialty pharmacy: prior authorization was consuming an outsized share of staff time and delaying patient access to medications, and the existing tooling was either too expensive for independent pharmacies, too inflexible for mixed payer environments, or not built with the actual workflow of a specialty pharmacy operations team in mind.
We spent the first two years building carefully and close to the ground — onboarding pharmacies in the Boston area, learning from their specific payer mixes and PMS configurations, understanding what "good" actually looked like before we tried to scale. That deliberate approach means we're announcing funding later than some startups, but it also means the product we're funding is one that we know works for real pharmacy teams handling real scripts with real payer complexity.
What We've Built and What We've Learned
The core of the Medsync platform is the parallel PA and benefits verification workflow: when a new specialty script arrives, we fire prior authorization requests and real-time BV checks simultaneously, eliminating the sequential wait that most pharmacies still run by default. For pharmacies that have been using Medsync, the change in average turnaround time has been the metric that sticks — scripts that used to take three to four days to fully process are completing within hours for the majority of their commercial payer submissions.
What we've also learned is that turnaround time is only part of the problem. The other part is the operational burden on benefits coordinators — the staff who spend their days navigating payer portals, fielding hold queues, and managing dozens of concurrent PA statuses simultaneously. Reducing their rote workload and giving them a clear, prioritized queue of scripts that actually need human attention has turned out to matter as much to pharmacy operations directors as the raw turnaround metric. The staff retention conversation keeps coming up in conversations with our customers, and we think there's more we can do there.
What the Funding Enables
The angel round gives us two things we've been constrained on: payer connectivity breadth and engineering capacity.
Payer connectivity is where the product's effectiveness has its ceiling. We have solid coverage across major commercial payers in our current geography, but specialty pharmacies serve mixed payer populations — Medicaid managed care organizations, regional Blues plans, Medicare Part D PDPs — and each of those requires its own integration work. Expanding payer connectivity means the platform handles a larger share of a pharmacy's submissions without fallback to manual, which is the metric that actually determines how much staff time we're saving.
Engineering capacity is about building faster without compromising on the things that matter in healthcare: data accuracy, PHI handling, and the reliability of a tool that pharmacy teams are depending on for time-sensitive patient care. We've kept a small team by design — focused, accountable, and close to the pharmacies we serve. This funding lets us add the engineering depth to accelerate without losing that discipline.
Where We're Focused
Our immediate focus is expanding our reach across New England and beginning to work with specialty pharmacies in adjacent markets. We're not announcing an ambitious 50-state expansion — that's not what angel funding is for, and it's not what our customers need from us right now. What they need is a product that handles more of their payer mix, integrates more cleanly with their pharmacy systems, and keeps getting better at identifying which scripts need urgent human attention before the clock runs out.
We're also continuing to build out the benefits verification side of the platform. Our earliest versions handled PA as the primary workflow and BV as a companion check. The more we've worked with pharmacy teams, the clearer it is that BV deserves to be a first-class feature in its own right — formulary status, deductible tracking, copay estimation, and coverage gap detection are tools that change what pharmacy teams can do for patients before a script is filled, not just after a PA comes back.
A Note on What We're Not Doing
Angel funding at this stage is a beginning, not an arrival. We're not announcing a massive team expansion, a pivot to a different market, or a product roadmap that requires raising more money before we deliver value. We're a specialty pharmacy operations tool, built by people who take that seriously. The problem is specific, the customers are real, and the work is ongoing.
If you're running a specialty pharmacy and prior authorization is where your team's time and energy is going, we'd like to show you what we've built. The best way to reach us is still directly — [email protected] — and we'll schedule a walkthrough that uses your actual script volume and payer mix, not a curated demo environment.
We're grateful to the people who have trusted us with their workflows and their feedback over the past few years. That trust is what this funding is built on, and it's the standard we're holding ourselves to as we grow.
